Morphofunctional analysis of the foveolar zone parameters with active CNV at AMD

Poster Details

First Author: M.Kalanov RUSSIA

Co Author(s):    R. Fayzrakhmanov                             

Abstract Details


Determination of macular zone parameters in patients with formation of fibrovascular membrane in wet form of age-related macular degeneration against the use of anti-VEGF therapy.


Ufa Eye Research Institute, Ufa, Russia.


The study included 35 patients (35 eyes) with active fibrovascular membrane in AMD. The average age of the patients was 68 ± 6,5 years, visual acuity - 0,1 ± 0,16. All patients underwent a threefold intravitreal injection of 0.05 ml (0.5 mg) inhibitor of angiogenesis - ranibizumab (LSR-004567/08, 2008-06-16, Novartis Pharma Stein AG, Switzerland) with an interval of 1 month. All patients underwent a complete ophthalmologic examination, including visiometry, perimetry, ophthalmoscopy. Additional studies were: Optical coherence tomography (OCT) with the apparatus RetinaScan - 3000 (NIDEK), microperimetry, which was performed using the device MP-1 (Nidek technologies) and the program 'Maculopathy'. The follow-up period included 3 months.


There was found an increase in the functional activity of the central retina from an average of 1.22 dB to 3.97 dB (p <0,05). On the background of the first injection of ranibizumab the total light sensitivity increased up to 4,22 ± 1,74 dB. After the second injection parameters of the functional mapping of the fundus was 4,37,04 ± 2,18 dB. Thus, when analyzing the data changes of the I sector microperimetry was revealed an increase of indicators from 2,29 ± 0,93 dB to 4,85 ± 1,82 dB (p <0,05). Pronounced hike in rates is determined after the first injection, the result of which is the increase in light sensitivity to an average of 6.12 dB (p <0,05, in comparison with the indices before treatment). After the second injection the sectoral mapping data of the central retina have not changed significantly (6.05 dB). According to the OCT on the background of threefold intravitreal injection of ranibizumab the height of the membrane decreased to an average of 113.03 m compared with the data obtained prior to the therapy (141,76 ± 42,91 mm). After the first course of anti-VEGF therapy the membrane height averaged 138.71 m, after the second - 133.29 m.


During the entire period of treatment was registered the change in morphological and functional parameters that demonstrates the effectiveness of anti-VEGF therapy. The most significant change in the functional parameters of the macular area occurs after the first course of the therapy. On this basis, in the formation of active fibrovascular membrane anti-VEGF therapy is effective only for a single intravitreal administration.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy